下载App
扫码立即下载
  • 下载App

    扫码立即下载

  • 在线客服

    登录后咨询在线客服
+
恭喜您!
成功领取价值超 5000港元/年的高级行情
前往体验 >>

BetterLife To Participate at the H.C. Wainwright 1st Annual Mental Health Conference
BetterLife将参加H.C.Wainwright首届精神健康年会

GlobeNewswire ·  {{timeTz}}

VANCOUVER, British Columbia, June 23, 2022 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. ("BetterLife" or the "Company") (CSE: BETR / OTCQB: BETRF / FRA: NPAU), an emerging biotech company focused on the development and commercialization of cutting-edge treatments for mental disorders, today announced that Dr. Ahmad Doroudian, Chief Executive Officer, will participate in a fireside chat at the upcoming H.C. Wainwright 1st Annual Mental Health Conference being held on June 27th, 2022 in New York City, NY.

温哥华,不列颠哥伦比亚省,2022年6月23日(环球网)--BetterLife Pharma Inc.(“BetterLife”或“公司”)(CSE:Betr/OTCQB:BETRF/FRA:NPAU),一家专注于精神障碍尖端疗法的开发和商业化的新兴生物技术公司,今天宣布,首席执行官Ahmad Doroudian博士将参加即将到来的H.C.Wainwright 1的炉边聊天ST一年一度的精神健康会议六月二十七日举行这是,2022年,纽约州纽约市。

The theme of the conference is "Neuropsychiatry, Psychedelics, and Beyond." The fireside chat will focus on the background of BetterLife and what differentiates it in the mental healthcare space.

这次会议的主题是“神经精神病学、迷幻学及以后”。炉边聊天将聚焦于BetterLife的背景以及它在精神保健领域的独特之处。

About BetterLife Pharma

关于BetterLife Pharma

BetterLife Pharma Inc. is an emerging biotechnology company primarily focused on developing and commercializing two compounds, BETR-001 and BETR-002, to treat neuro-psychiatric and neurological disorders.

BetterLife制药公司是一家新兴的生物技术公司,主要致力于开发和商业化两种化合物BETR-001和BETR-002,用于治疗神经精神和神经疾病。

BETR-001, which is in preclinical and IND-enabling studies, is a non-hallucinogenic and non-controlled LSD derivative in development and it is unique in that it is unregulated and therefore can be self-administered. BetterLife's synthesis patent for BETR-001 eliminates regulatory hurdles and its pending patent for composition and method of use covers treatment of depression, cluster headaches, post-traumatic stress disorder and other neuro-psychiatric and neurological disorders.

Betr-001处于临床前研究和IND使能研究中,是一种开发中的非致幻和非受控LSD衍生物,其独特之处在于它不受监管,因此可以自我给药。BetterLife用于BETR-001的合成专利消除了管理障碍,其正在申请的组合物和使用方法专利涵盖治疗抑郁症、丛集性头痛、创伤后应激障碍和其他神经精神和神经障碍。

BETR-002, which is in preclinical and IND-enabling studies, is based on honokiol, the active anxiolytic ingredient of magnolia bark. BetterLife's pending method of use and formulations patent covers treatment of anxiety related disorders including benzodiazepine dependency.

Betr-002正在进行临床前和IND的研究,它是基于厚朴酚的,和厚朴酚是厚朴树皮的有效抗焦虑成分。BetterLife正在申请的使用方法和配方专利涵盖了治疗焦虑症相关疾病,包括对苯二氮卓的依赖。

BetterLife also owns a drug candidate for the treatment of viral infections such as COVID-19 and is in the process of seeking strategic alternatives for further development.

BetterLife还拥有一种治疗新冠肺炎等病毒感染的候选药物,并正在寻找进一步发展的战略替代药物。

For further information, please visit BetterLife Pharma.

欲了解更多信息,请访问BetterLife Pharma。

Contact Information

联系信息

David Melles, Investor Relations Manager
Email: David.Melles@blifepharma.com
Phone: 1-778-887-1928

投资者关系经理大卫·梅尔斯
电子邮件:David.Melle@blifepharma.com
电话:1-778-887-1928

Cautionary Note Regarding Forward-Looking Statements

有关前瞻性陈述的注意事项

No securities exchange has reviewed nor accepts responsibility for the adequacy or accuracy of the content of this news release. This news release contains forward-looking statements relating to product development, licensing, commercialization and regulatory compliance issues and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the Company's expectations include the failure to satisfy the conditions of the relevant securities exchange(s) and other risks detailed from time to time in the filings made by the Company with securities regulations. The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by applicable law.

没有任何证券交易所对本新闻稿内容的充分性或准确性进行审查或承担责任。本新闻稿包含与产品开发、许可、商业化和监管合规问题有关的前瞻性陈述,以及其他非历史事实的陈述。前瞻性陈述通常用“将”、“可能”、“应该”、“预期”、“预期”和类似的表达方式来识别。除历史事实陈述外,本新闻稿中包含的所有陈述均为前瞻性陈述,涉及风险和不确定性。不能保证这些陈述将被证明是准确的,实际结果和未来事件可能与这些陈述中预期的大不相同。可能导致实际结果与公司预期大相径庭的重要因素包括未能满足相关证券交易所的条件以及公司不时提交给证券监管机构的文件中详述的其他风险。提醒读者,在准备任何前瞻性信息时使用的假设可能被证明是不正确的。由于许多已知和未知的风险、不确定性和其他因素,其中许多是公司无法控制的,事件或情况可能会导致实际结果与预测的结果大不相同。提醒读者不要过度依赖任何前瞻性信息。这种信息,尽管在准备时管理层认为是合理的, 可能被证明是不正确的,实际结果可能与预期的大不相同。本新闻稿中包含的前瞻性陈述明确地受到本警示性声明的限制。本新闻稿中包含的前瞻性陈述是截至本新闻稿发布之日作出的,公司将根据适用法律的明确要求,公开更新或修改任何包含的前瞻性陈述。


本页的译文内容由软件翻译。富途将竭力但却不能保证翻译内容之准确和可靠,亦不会承担因任何不准确或遗漏而引起的任何损失或损害。

风险提示:以上内容仅作为作者或者嘉宾的观点,不代表富途的任何立场,不构成与富途相关的任何投资建议。在作出任何投资决定前,投资者应根据自身情况考虑投资产品相关的风险因素,并于需要时咨询专业投资顾问意见。富途竭力但不能证实上述内容的真实性、准确性和原创性,对此富途不做任何保证和承诺。